CITIC Securities: Maintaining Giant Biotech's (02367) “Buy” Rating Target Price of HK$44

Zhitongcaijing · 3d ago

The Zhitong Finance App learned that CITIC Securities released a research report saying that due to the influence of the industry environment and trade-offs in corporate operation decisions, Juzi Biotech (02367) Double Eleven sales were under pressure, lowering revenue and profit forecasts for 2025; at the same time, the company's brand assets are solid, and there are structural highlights in operation. Looking forward to the future, the company has clear ideas for the short, medium and long term. Fumei can set a revenue target of 10 billion dollars and formulate clear plans in terms of product/operation/channels. Clekin will carry out brand reshaping while promoting new products, and it is expected that it will build a second popular OTC brand. The revenue and profit forecasts for 2025 were adjusted to $5.49 billion/$1.93 billion, respectively, and adjusted net profit forecasts to $1.98 billion, to give 2026 20x PE with a target price of HK$44, maintaining the “buy” rating.